{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T08:40:24Z","timestamp":1792312824499,"version":"4.4.0"},"reference-count":157,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T00:00:00Z","timestamp":1788652800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T00:00:00Z","timestamp":1788652800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014354","name":"Milstein Medical Asian American Partnership Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014354","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s40121-026-01434-0","type":"journal-article","created":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T18:04:27Z","timestamp":1788717867000},"page":"2839-2864","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Burden of Invasive Meningococcal Disease: Evolving Epidemiology and Implications for Prevention Policy"],"prefix":"10.1007","volume":"15","author":[{"given":"Mary","family":"Bausch-Jurken","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Leng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Pelton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,6]]},"reference":[{"issue":"18","key":"1434_CR1","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1056\/NEJM200105033441807","volume":"344","author":"NE Rosenstein","year":"2001","unstructured":"Rosenstein NE, Perkins BA, Stephens DS, Popovic T, Hughes JM. Meningococcal disease. N Engl J Med. 2001;344(18):1378\u201388. https:\/\/doi.org\/10.1056\/NEJM200105033441807.","journal-title":"N Engl J Med"},{"issue":"9","key":"1434_CR2","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/S1474-4422(12)70180-1","volume":"11","author":"RM Viner","year":"2012","unstructured":"Viner RM, Booy R, Johnson H, et al. Outcomes of invasive meningococcal serogroup B disease in children and adolescents (MOSAIC): a case-control study. Lancet Neurol. 2012;11(9):774\u201383. https:\/\/doi.org\/10.1016\/S1474-4422(12)70180-1.","journal-title":"Lancet Neurol"},{"issue":"7","key":"1434_CR3","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1007\/s40121-025-01166-7","volume":"14","author":"J Presa","year":"2025","unstructured":"Presa J, Carrico R, Fergie JE, et al. Preventing meningococcal disease in US adolescents and young adults through vaccination. Infect Dis Ther. 2025;14(7):1381\u2013403. https:\/\/doi.org\/10.1007\/s40121-025-01166-7.","journal-title":"Infect Dis Ther"},{"key":"1434_CR4","first-page":"204","volume-title":"Epidemiology and prevention of vaccine-preventable diseases","author":"SA Mbaeyi","year":"2024","unstructured":"Mbaeyi SA, Duffy J, McNamara LA. Meningococcal disease. In: Hall E, Wodie AP, Hamborsky J, Morelli V, Schilli S, editors. Epidemiology and prevention of vaccine-preventable diseases. Centers for Disease Control and Prevention; 2024. p. 204\u201324."},{"key":"1434_CR5","volume-title":"Annual epidemiological report for 2023","author":"European Centre for Disease Prevention and Control","year":"2025","unstructured":"European Centre for Disease Prevention and Control. Annual epidemiological report for 2023: invasive meningococcal disease. In: Annual epidemiological report for 2023. Stockholm: European Centre for Disease Prevention and Control; 2025."},{"key":"1434_CR6","unstructured":"Centers for Disease Control and Prevention. Meningococcal disease surveillance and trends. https:\/\/www.cdc.gov\/meningococcal\/php\/surveillance\/index.html. Accessed April 28 2026."},{"issue":"21","key":"1434_CR7","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1016\/j.vaccine.2019.04.020","volume":"37","author":"B Wang","year":"2019","unstructured":"Wang B, Santoreneos R, Giles L, Haji Ali Afzali H, Marshall H. Case fatality rates of invasive meningococcal disease by serogroup and age: a systematic review and meta-analysis. Vaccine. 2019;37(21):2768\u201382. https:\/\/doi.org\/10.1016\/j.vaccine.2019.04.020.","journal-title":"Vaccine"},{"issue":"8","key":"1434_CR8","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1093\/cid\/cix993","volume":"66","author":"JR MacNeil","year":"2018","unstructured":"MacNeil JR, Blain AE, Wang X, Cohn AC. Current epidemiology and trends in meningococcal disease\u2014United States, 1996\u20132015. Clin Infect Dis. 2018;66(8):1276\u201381. https:\/\/doi.org\/10.1093\/cid\/cix993.","journal-title":"Clin Infect Dis"},{"issue":"10","key":"1434_CR9","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1007\/s40121-023-00869-z","volume":"12","author":"I Bertrand-Gerentes","year":"2023","unstructured":"Bertrand-Gerentes I, Fanchon L, Coste F, Glover RE, Guiddir T, Taha M-K. Range of clinical manifestations caused by invasive meningococcal disease due to serogroup W: a systematic review. Infect Dis Ther. 2023;12(10):2337\u201351. https:\/\/doi.org\/10.1007\/s40121-023-00869-z.","journal-title":"Infect Dis Ther"},{"key":"1434_CR10","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268819002152","volume":"148","author":"C Stinson","year":"2020","unstructured":"Stinson C, Burman C, Presa J, Abalos M. Atypical presentation of invasive meningococcal disease caused by serogroup W meningococci. Epidemiol Infect. 2020;148:e12. https:\/\/doi.org\/10.1017\/S0950268819002152.","journal-title":"Epidemiol Infect"},{"issue":"4","key":"1434_CR11","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s40121-018-0213-2","volume":"7","author":"KJ Olbrich","year":"2018","unstructured":"Olbrich KJ, M\u00fcller D, Schumacher S, Beck E, Meszaros K, Koerber F. Systematic review of invasive meningococcal disease: sequelae and quality of life impact on patients and their caregivers. Infect Dis Ther. 2018;7(4):421\u201338. https:\/\/doi.org\/10.1007\/s40121-018-0213-2.","journal-title":"Infect Dis Ther"},{"key":"1434_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2023.100640","volume":"30","author":"TM van Soest","year":"2023","unstructured":"van Soest TM, Chekrouni N, van Sorge NM, Bijlsma MW, Brouwer MC, van de Beek D. Epidemiology, clinical features and outcome of adults with meningococcal meningitis: a 15-year prospective nationwide cohort study. Lancet Reg Health Eur. 2023;30:100640. https:\/\/doi.org\/10.1016\/j.lanepe.2023.100640.","journal-title":"Lancet Reg Health Eur"},{"issue":"8","key":"1434_CR13","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1007\/s40121-025-01181-8","volume":"14","author":"T Wolynn","year":"2025","unstructured":"Wolynn T, Grimes JB, Nerurkar S, et al. Long-term impacts of invasive meningococcal disease on survivors and their caregivers in the United States and Canada. Infect Dis Ther. 2025;14(8):1577\u201397. https:\/\/doi.org\/10.1007\/s40121-025-01181-8.","journal-title":"Infect Dis Ther"},{"issue":"4 suppl 2","key":"1434_CR14","doi-asserted-by":"publisher","first-page":"B64","DOI":"10.1016\/j.vaccine.2009.04.061","volume":"27","author":"DA Caugant","year":"2009","unstructured":"Caugant DA, Maiden MCJ. Meningococcal carriage and disease\u2014population biology and evolution. Vaccine. 2009;27(4 suppl 2):B64-70. https:\/\/doi.org\/10.1016\/j.vaccine.2009.04.061.","journal-title":"Vaccine"},{"key":"1434_CR15","doi-asserted-by":"publisher","first-page":"e57","DOI":"10.1017\/S0950268823000328","volume":"151","author":"C Pardo de Santayana","year":"2023","unstructured":"Pardo de Santayana C, Tin Tin Htar M, Findlow J, Balmer P. Epidemiology of invasive meningococcal disease worldwide from 2010\u20132019: a literature review. Epidemiol Infect. 2023;151:e57. https:\/\/doi.org\/10.1017\/S0950268823000328.","journal-title":"Epidemiol Infect"},{"issue":"3","key":"1434_CR16","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s40272-024-00666-2","volume":"27","author":"S Schillie","year":"2025","unstructured":"Schillie S, McNamara LA. Meningococcal vaccination in the United States: past, present, and future. Paediatr Drugs. 2025;27(3):331\u201349. https:\/\/doi.org\/10.1007\/s40272-024-00666-2.","journal-title":"Paediatr Drugs"},{"key":"1434_CR17","unstructured":"World Health Organization. Meningococcal vaccines: WHO position paper on the use of multivalent meningococcal conjugate vaccines in countries of the African meningitis belt, January 2024. https:\/\/www.who.int\/publications\/i\/item\/who-wer9901-02-1-10."},{"key":"1434_CR18","unstructured":"World Health Organization. Meningococcal meningitis. https:\/\/www.who.int\/teams\/health-product-policy-and-standards\/standards-and-specifications\/norms-and-standards\/vaccine-standardization\/meningococcal-meningitis. Accessed April 28, 2026."},{"issue":"12","key":"1434_CR19","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/S1473-3099(10)70251-6","volume":"10","author":"H Christensen","year":"2010","unstructured":"Christensen H, May M, Bowen L, Hickman M, Trotter CL. Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect Dis. 2010;10(12):853\u201361. https:\/\/doi.org\/10.1016\/S1473-3099(10)70251-6.","journal-title":"Lancet Infect Dis"},{"key":"1434_CR20","doi-asserted-by":"publisher","DOI":"10.11604\/pamj.2021.39.57.17629","volume":"39","author":"A Jaca","year":"2021","unstructured":"Jaca A, Wiyeh AB, Sambala EZ, Wiysonge CS. The burden of meningococcal meningitis in the African Meningitis Belt, from 2009 to 2014: a trend analysis. Pan Afr Med J. 2021;39:57. https:\/\/doi.org\/10.11604\/pamj.2021.39.57.17629.","journal-title":"Pan Afr Med J"},{"key":"1434_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-025-24787-6","volume":"25","author":"D-D Li","year":"2025","unstructured":"Li D-D, Sang X-Q, Huang Q, et al. Trends in the global burden of childhood meningitis between 1990 and 2021 and projections to 2035: based on the global burden of diseases database 2021. BMC Public Health. 2025;25:3404. https:\/\/doi.org\/10.1186\/s12889-025-24787-6.","journal-title":"BMC Public Health"},{"issue":"11","key":"1434_CR22","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1016\/S1473-3099(15)00217-0","volume":"15","author":"S Sridhar","year":"2015","unstructured":"Sridhar S, Greenwood B, Head C, et al. Global incidence of serogroup B invasive meningococcal disease: a systematic review. Lancet Infect Dis. 2015;15(11):1334\u201346. https:\/\/doi.org\/10.1016\/S1473-3099(15)00217-0.","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"1434_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2025.106635","volume":"91","author":"R Borrow","year":"2025","unstructured":"Borrow R, Caugant DA, Clark SA, et al. Current global trends in meningococcal disease control, risk groups and vaccination: consensus of the Global Meningococcal Initiative. J Infect. 2025;91(5):106635. https:\/\/doi.org\/10.1016\/j.jinf.2025.106635.","journal-title":"J Infect"},{"issue":"2","key":"1434_CR24","doi-asserted-by":"publisher","first-page":"165","DOI":"10.3390\/vaccines13020165","volume":"13","author":"J Findlow","year":"2025","unstructured":"Findlow J, Htar MTT, Villena R, Balmer P. Invasive meningococcal disease in the post-COVID world: patterns of disease rebound. Vaccines. 2025;13(2):165. https:\/\/doi.org\/10.3390\/vaccines13020165.","journal-title":"Vaccines"},{"issue":"6","key":"1434_CR25","doi-asserted-by":"publisher","first-page":"e360","DOI":"10.1016\/S2589-7500(21)00077-7","volume":"3","author":"AB Brueggemann","year":"2021","unstructured":"Brueggemann AB, Jansen van Rensburg MJ, Shaw D, et al. Changes in the incidence of invasive disease due to Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria meningitidis during the COVID-19 pandemic in 26 countries and territories in the Invasive Respiratory Infection Surveillance Initiative: a prospective analysis of surveillance data. Lancet Digit Health. 2021;3(6):e360\u201370. https:\/\/doi.org\/10.1016\/S2589-7500(21)00077-7.","journal-title":"Lancet Digit Health"},{"key":"1434_CR26","unstructured":"Champions for Vaccine Education, Equity, and Progress (CVEEP). Shared clinical decision making for vaccines. https:\/\/cveep.org\/wp-content\/uploads\/2024\/09\/CVEEP_SCDM.pdf."},{"key":"1434_CR27","unstructured":"Sekar K. The Advisory Committee on Immunization Practices (ACIP). https:\/\/www.congress.gov\/crs-product\/IF12317."},{"key":"1434_CR28","doi-asserted-by":"publisher","first-page":"1694023","DOI":"10.3389\/fpubh.2026.1694023","volume":"14","author":"J Presa","year":"2026","unstructured":"Presa J, Spitz D, Balmer P, Snow V, Dooling K. Epidemiology of invasive meningococcal disease in the United States: review of recent data and identified risk factors. Front Publ Health. 2026;14:1694023. https:\/\/doi.org\/10.3389\/fpubh.2026.1694023.","journal-title":"Front Publ Health"},{"key":"1434_CR29","unstructured":"Centers for Disease Control and Prevention. Increase in Invasive Serogroup Y Meningococcal Disease in the United States. CDC Health Alert Network (HAN). CDCHAN-00505. https:\/\/www.cdc.gov\/han\/2024\/han00505.html."},{"issue":"5","key":"1434_CR30","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz190","volume":"6","author":"LA McNamara","year":"2011","unstructured":"McNamara LA, Potts CC, Blain A, et al. Invasive meningococcal disease due to nongroupable Neisseria meningitidis-active bacterial core surveillance sites, 2011-2016. Open Forum Infect Dis. 2011;6(5):ofz190. https:\/\/doi.org\/10.1093\/ofid\/ofz190.","journal-title":"Open Forum Infect Dis"},{"issue":"30","key":"1434_CR31","doi-asserted-by":"publisher","first-page":"466","DOI":"10.15585\/mmwr.mm7430a1","volume":"74","author":"C Pingali","year":"2025","unstructured":"Pingali C, Yankey D, Elam-Evans LD, et al. Vaccination coverage among adolescents aged 13\u201317 years - National Immunization Survey-Teen United States 2024. MMWR Morb Mortal Wkly Rep. 2025;74(30):466\u201372. https:\/\/doi.org\/10.15585\/mmwr.mm7430a1.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"1434_CR32","unstructured":"BEXSERO (MenB). Prescribing information. GlaxoSmithKline; 2024."},{"key":"1434_CR33","unstructured":"TRUMENBA (MenB). Prescribing information. Pfizer Inc.; 2024."},{"issue":"1","key":"1434_CR34","doi-asserted-by":"publisher","first-page":"2165382","DOI":"10.1080\/21645515.2023.2165382","volume":"19","author":"ER Packnett","year":"2023","unstructured":"Packnett ER, Zimmerman NM, Novy P, Morgan LC, Chime N, Ghaswalla P. Meningococcal serogroup B vaccination series initiation in the United States: a real-world claims data analysis. Hum Vaccin Immunother. 2023;19(1):2165382. https:\/\/doi.org\/10.1080\/21645515.2023.2165382.","journal-title":"Hum Vaccin Immunother"},{"issue":"4","key":"1434_CR35","doi-asserted-by":"publisher","first-page":"e158","DOI":"10.1097\/INF.0000000000003455","volume":"41","author":"ER Packnett","year":"2022","unstructured":"Packnett ER, Zimmerman NM, Kim G, et al. A real-world claims data analysis of meningococcal serogroup B vaccine series completion and potential missed opportunities in the United States. Pediatr Infect Dis J. 2022;41(4):e158\u201365. https:\/\/doi.org\/10.1097\/INF.0000000000003455.","journal-title":"Pediatr Infect Dis J"},{"issue":"2","key":"1434_CR36","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.vaccine.2020.11.068","volume":"39","author":"PK Ghaswalla","year":"2021","unstructured":"Ghaswalla PK, Bengtson LGS, Marshall GS, et al. Meningococcal vaccination in patients with newly diagnosed asplenia in the United States. Vaccine. 2021;39(2):272\u201381. https:\/\/doi.org\/10.1016\/j.vaccine.2020.11.068.","journal-title":"Vaccine"},{"issue":"4","key":"1434_CR37","doi-asserted-by":"publisher","first-page":"e228573","DOI":"10.1001\/jamanetworkopen.2022.8573","volume":"5","author":"PK Ghaswalla","year":"2022","unstructured":"Ghaswalla PK, Marshall GS, Bengtson LGS, et al. Meningococcal vaccination rates among people with a new diagnosis of HIV infection in the US. JAMA Netw Open. 2022;5(4):e228573. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.8573.","journal-title":"JAMA Netw Open"},{"issue":"1","key":"1434_CR38","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1093\/cid\/ciab917","volume":"75","author":"GS Marshall","year":"2022","unstructured":"Marshall GS, Ghaswalla PK, Bengtson LGS, et al. Low meningococcal vaccination rates among patients with newly diagnosed complement component deficiencies in the United States. Clin Infect Dis. 2022;75(1):155\u20138. https:\/\/doi.org\/10.1093\/cid\/ciab917.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"1434_CR39","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1007\/s40121-023-00793-2","volume":"12","author":"O Herrera-Restrepo","year":"2023","unstructured":"Herrera-Restrepo O, Kuang Y, D\u2019Angelo J, Bekkat-Berkani R, Clements DE, Uyei J. Determinants of meningococcal vaccination coverage and adherence: a targeted literature review supporting a 16-year-old healthcare visit. Infect Dis Ther. 2023;12(5):1265\u201382. https:\/\/doi.org\/10.1007\/s40121-023-00793-2.","journal-title":"Infect Dis Ther"},{"issue":"6","key":"1434_CR40","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1016\/j.jadohealth.2023.11.394","volume":"74","author":"O Herrera-Restrepo","year":"2024","unstructured":"Herrera-Restrepo O, Bunniran S, Mond T, et al. United States physicians\u2019 knowledge, attitudes, and practices regarding meningococcal vaccination for healthy adolescents and young adults. J Adolesc Health. 2024;74(6):1131\u20138. https:\/\/doi.org\/10.1016\/j.jadohealth.2023.11.394.","journal-title":"J Adolesc Health"},{"issue":"7","key":"1434_CR41","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1080\/03007995.2024.2362924","volume":"40","author":"O Herrera-Restrepo","year":"2024","unstructured":"Herrera-Restrepo O, Clements DE, Hebert ZN, McCracken C. Exploring meningococcal serogroup B vaccination conversations under shared clinical decision-making in the US. Curr Med Res Opin. 2024;40(7):1253\u201363. https:\/\/doi.org\/10.1080\/03007995.2024.2362924.","journal-title":"Curr Med Res Opin"},{"issue":"4","key":"1434_CR42","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.jadohealth.2024.11.248","volume":"76","author":"O Herrera-Restrepo","year":"2025","unstructured":"Herrera-Restrepo O, Clements DE, Olaiya T, Marshall GS. Knowledge, attitudes, and practices regarding meningococcal vaccination since the 2015 recommendation: a review. J Adolesc Health. 2025;76(4):558\u201370. https:\/\/doi.org\/10.1016\/j.jadohealth.2024.11.248.","journal-title":"J Adolesc Health"},{"issue":"4","key":"1434_CR43","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1093\/cid\/ciy548","volume":"68","author":"SA Mbaeyi","year":"2019","unstructured":"Mbaeyi SA, Blain A, Whaley MJ, Wang X, Cohn AC, MacNeil JR. Epidemiology of meningococcal disease outbreaks in the United States, 2009\u20132013. Clin Infect Dis. 2019;68(4):580\u20135. https:\/\/doi.org\/10.1093\/cid\/ciy548.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"1434_CR44","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41541-024-00809-z","volume":"9","author":"CH Jones","year":"2024","unstructured":"Jones CH, Jenkins MP, Adam Williams B, Welch VL, True JM. Exploring the future adult vaccine landscape\u2014crowded schedules and new dynamics. NPJ Vaccines. 2024;9(1):27. https:\/\/doi.org\/10.1038\/s41541-024-00809-z.","journal-title":"NPJ Vaccines"},{"issue":"3","key":"1434_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.ss7003a1","volume":"70","author":"P-J Lu","year":"2021","unstructured":"Lu P-J, Hung M-C, Srivastav A, et al. Surveillance of vaccination coverage among adult populations\u2014United States, 2018. MMWR Surveill Summ. 2021;70(3):1\u201326. https:\/\/doi.org\/10.15585\/mmwr.ss7003a1.","journal-title":"MMWR Surveill Summ"},{"issue":"9","key":"1434_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr6909a1","volume":"69","author":"SA Mbaeyi","year":"2020","unstructured":"Mbaeyi SA, Bozio CH, Duffy J, et al. Meningococcal vaccination: recommendations of the Advisory Committee on Immunization Practices, United States, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(9):1\u201341. https:\/\/doi.org\/10.15585\/mmwr.rr6909a1.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"6","key":"1434_CR47","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0319940","volume":"20","author":"AB Rubis","year":"2025","unstructured":"Rubis AB, Marasini D, Howie R, et al. Enhanced surveillance for meningococcal disease\u2014United States, 2015-2019. PLoS ONE. 2025;20(6):e0319940. https:\/\/doi.org\/10.1371\/journal.pone.0319940.","journal-title":"PLoS ONE"},{"key":"1434_CR48","unstructured":"Centers\u00a0for\u00a0Disease\u00a0Control\u00a0and\u00a0Prevention. Risk Factors for Meningococcal Disease. https:\/\/www.cdc.gov\/meningococcal\/risk-factors\/index.html. Accessed 2 June 2026."},{"issue":"4","key":"1434_CR49","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1056\/NEJMoa1901229","volume":"382","author":"SN Ladhani","year":"2020","unstructured":"Ladhani SN, Andrews N, Parikh SR, et al. Vaccination of infants with meningococcal group B vaccine (4CMenB) in England. N Engl J Med. 2020;382(4):309\u201317. https:\/\/doi.org\/10.1056\/NEJMoa1901229.","journal-title":"N Engl J Med"},{"issue":"2","key":"1434_CR50","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1080\/20477724.2021.1972663","volume":"116","author":"F Martin\u00f3n-Torres","year":"2022","unstructured":"Martin\u00f3n-Torres F, Taha MK, Knuf M, et al. Evolving strategies for meningococcal vaccination in Europe: overview and key determinants for current and future considerations. Pathog Glob Health. 2022;116(2):85\u201398. https:\/\/doi.org\/10.1080\/20477724.2021.1972663.","journal-title":"Pathog Glob Health"},{"key":"1434_CR51","unstructured":"PENBRAYA (MenABCWY). Prescribing information. Pfizer Inc.; 2026."},{"key":"1434_CR52","unstructured":"PENMENVY (MenABCWY). Prescribing information. GlaxoSmithKline; 2025."},{"issue":"1","key":"1434_CR53","doi-asserted-by":"publisher","first-page":"7","DOI":"10.15585\/mmwr.mm7501a2","volume":"75","author":"AB Amin","year":"2026","unstructured":"Amin AB, Collins JP, Dong X, et al. Use of the GSK MenACWY-CRM\/MenB-4C pentavalent meningococcal vaccine among persons aged \u226510 years: recommendations of the Advisory Committee on Immunization Practices - United States, 2025. MMWR Morb Mortal Wkly Rep. 2026;75(1):7\u201314. https:\/\/doi.org\/10.15585\/mmwr.mm7501a2.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"1434_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2026.108502","volume":"166","author":"S Yezli","year":"2026","unstructured":"Yezli S, Bonanni P, Dinleyici EC, et al. Invasive meningococcal disease rebound in older adults post-COVID-19 pandemic: a targeted literature and surveillance review. Int J Infect Dis. 2026;166:108502. https:\/\/doi.org\/10.1016\/j.ijid.2026.108502.","journal-title":"Int J Infect Dis"},{"issue":"5","key":"1434_CR55","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/S1473-3099(10)70048-7","volume":"10","author":"K Edmond","year":"2010","unstructured":"Edmond K, Clark A, Korczak VS, Sanderson C, Griffiths UK, Rudan I. Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis. Lancet Infect Dis. 2010;10(5):317\u201328. https:\/\/doi.org\/10.1016\/S1473-3099(10)70048-7.","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"1434_CR56","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1093\/jpids\/pir003","volume":"1","author":"R Judelsohn","year":"2012","unstructured":"Judelsohn R, Marshall GS. The burden of infant meningococcal disease in the United States. J Pediatr Infect Dis Soc. 2012;1(1):64\u201373. https:\/\/doi.org\/10.1093\/jpids\/pir003.","journal-title":"J Pediatr Infect Dis Soc"},{"issue":"4","key":"1434_CR57","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms13040705","volume":"13","author":"P Poulikakos","year":"2025","unstructured":"Poulikakos P, Kapnisis D, Xirogianni A, et al. Invasive meningococcal disease in children: outcomes and risk factors for sequelae and fatal cases in Greece. Microorganisms. 2025;13(4):705. https:\/\/doi.org\/10.3390\/microorganisms13040705.","journal-title":"Microorganisms"},{"issue":"7","key":"1434_CR58","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1097\/INF.0000000000000282","volume":"33","author":"C Stein-Zamir","year":"2014","unstructured":"Stein-Zamir C, Shoob H, Sokolov I, Kunbar A, Abramson N, Zimmerman D. The clinical features and long-term sequelae of invasive meningococcal disease in children. Pediatr Infect Dis J. 2014;33(7):777\u20139. https:\/\/doi.org\/10.1097\/INF.0000000000000282.","journal-title":"Pediatr Infect Dis J"},{"issue":"14","key":"1434_CR59","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1016\/S0264-410X(98)00098-X","volume":"16","author":"GT Rijkers","year":"1998","unstructured":"Rijkers GT, Sanders EAM, Breukels MA, Zegers BJM. Infant B cell responses to polysaccharide determinants. Vaccine. 1998;16(14):1396\u2013400. https:\/\/doi.org\/10.1016\/S0264-410X(98)00098-X.","journal-title":"Vaccine"},{"issue":"1","key":"1434_CR60","doi-asserted-by":"publisher","DOI":"10.1155\/2008\/628963","volume":"2008","author":"P Klein Klouwenberg","year":"2008","unstructured":"Klein Klouwenberg P, Bont L. Neonatal and infantile immune responses to encapsulated bacteria and conjugate vaccines. J Immunol Res. 2008;2008(1):628963. https:\/\/doi.org\/10.1155\/2008\/628963.","journal-title":"J Immunol Res"},{"issue":"6","key":"1434_CR61","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1136\/jcp.56.6.417","volume":"56","author":"AJ Kvalsvig","year":"2003","unstructured":"Kvalsvig AJ, Unsworth DJ. The immunopathogenesis of meningococcal disease. J Clin Pathol. 2003;56(6):417\u201322. https:\/\/doi.org\/10.1136\/jcp.56.6.417.","journal-title":"J Clin Pathol"},{"issue":"9","key":"1434_CR62","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1007\/s10096-020-03894-9","volume":"39","author":"L-M Steurer","year":"2020","unstructured":"Steurer L-M, Hetzmannseder M, Willinger B, et al. Pharyngeal carriage rates of Neisseria meningitidis in health care professionals at a tertiary university pediatric hospital. Eur J Clin Microbiol Infect Dis. 2020;39(9):1703\u20139. https:\/\/doi.org\/10.1007\/s10096-020-03894-9.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"3","key":"1434_CR63","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1017\/S0950268801005817","volume":"127","author":"T Grein","year":"2001","unstructured":"Grein T, O\u2019Flanagan D. Day-care and meningococcal disease in young children. Epidemiol Infect. 2001;127(3):435\u201341. https:\/\/doi.org\/10.1017\/S0950268801005817.","journal-title":"Epidemiol Infect"},{"issue":"12","key":"1434_CR64","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0337446","volume":"20","author":"P Vacca","year":"2025","unstructured":"Vacca P, Vescio F, D\u2019Ancona F, et al. Neisseria meningitidis serogroup B causing invasive disease, Italy, 2010\u20132021. PLoS ONE. 2025;20(12):e0337446. https:\/\/doi.org\/10.1371\/journal.pone.0337446.","journal-title":"PLoS ONE"},{"issue":"1","key":"1434_CR65","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/s43856-025-00800-2","volume":"5","author":"M Falgui\u00e8res","year":"2025","unstructured":"Falgui\u00e8res M, Hong E, Denizon M, Terrade A, Taha MK, Deghmane AE. Fluctuations in serogroup B meningococcal vaccine antigens prior to routine MenB vaccination in France. Commun Med (Lond). 2025;5(1):87. https:\/\/doi.org\/10.1038\/s43856-025-00800-2.","journal-title":"Commun Med (Lond)"},{"issue":"4","key":"1434_CR66","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.jinf.2020.05.079","volume":"81","author":"SR Parikh","year":"2020","unstructured":"Parikh SR, Campbell H, Bettinger JA, et al. The everchanging epidemiology of meningococcal disease worldwide and the potential for prevention through vaccination. J Infect. 2020;81(4):483\u201398. https:\/\/doi.org\/10.1016\/j.jinf.2020.05.079.","journal-title":"J Infect"},{"issue":"4","key":"1434_CR67","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1056\/NEJMoa1900236","volume":"382","author":"HS Marshall","year":"2020","unstructured":"Marshall HS, McMillan M, Koehler AP, et al. Meningococcal B vaccine and meningococcal carriage in adolescents in Australia. N Engl J Med. 2020;382(4):318\u201327. https:\/\/doi.org\/10.1056\/NEJMoa1900236.","journal-title":"N Engl J Med"},{"issue":"3","key":"1434_CR68","doi-asserted-by":"publisher","first-page":"434","DOI":"10.3201\/eid2503.181574","volume":"25","author":"HM Soeters","year":"2019","unstructured":"Soeters HM, McNamara LA, Blain AE, et al. University-based outbreaks of meningococcal disease caused by serogroup B, United States, 2013-2018. Emerg Infect Dis. 2019;25(3):434\u201340. https:\/\/doi.org\/10.3201\/eid2503.181574.","journal-title":"Emerg Infect Dis"},{"issue":"9","key":"1434_CR69","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1093\/infdis\/jix446","volume":"216","author":"LA McNamara","year":"2017","unstructured":"McNamara LA, Thomas JD, MacNeil J, et al. Meningococcal carriage following a vaccination campaign with MenB-4C and MenB-FHbp in response to a university serogroup B meningococcal disease outbreak\u2014Oregon, 2015\u20132016. J Infect Dis. 2017;216(9):1130\u201340. https:\/\/doi.org\/10.1093\/infdis\/jix446.","journal-title":"J Infect Dis"},{"issue":"1","key":"1434_CR70","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1080\/14760584.2024.2329618","volume":"23","author":"R Borrow","year":"2024","unstructured":"Borrow R, Findlow J. The important lessons lurking in the history of meningococcal epidemiology. Expert Rev Vaccines. 2024;23(1):445\u201362. https:\/\/doi.org\/10.1080\/14760584.2024.2329618.","journal-title":"Expert Rev Vaccines"},{"key":"1434_CR71","unstructured":"World Health Organization. Meningitis Weekly Bulletin Week 49 - 52, 2024. https:\/\/cdn.who.int\/media\/docs\/default-source\/documents\/emergencies\/health-topics---meningitis\/weekly-bulletin-meningite_2024_s49-52.pdf?sfvrsn=bc64357e_1&download=true. Accessed June 4, 2026."},{"key":"1434_CR72","unstructured":"World Health Organization. Meningitis Weekly Bulletin 30 June to 3 August 2025. https:\/\/www.who.int\/publications\/m\/item\/meningitis-weekly-bulletin-30-june-to-3-august-2025. Accessed June 4, 2026."},{"issue":"Suppl 1","key":"1434_CR73","doi-asserted-by":"publisher","first-page":"ofaf695.82","DOI":"10.1093\/ofid\/ofaf695.682","volume":"13","author":"Z Kocaata","year":"2026","unstructured":"Kocaata Z, Gaianu L, Ubamadu I, et al. P-467 Prevalence of meningococcal carriage by serogroup in adolescents: a global systematic literature review. Open Forum Infect Dis. 2026;13(Suppl 1):ofaf695.82. https:\/\/doi.org\/10.1093\/ofid\/ofaf695.682.","journal-title":"Open Forum Infect Dis."},{"issue":"1","key":"1434_CR74","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2025.2574129","volume":"21","author":"A Andani","year":"2025","unstructured":"Andani A, Abbing-Karahagopian V, Kavaliauskaite J, et al. Invasive meningococcal disease in adolescents in Europe and select geographies: disease burden, unmet medical need, and optimizing prevention. Hum Vaccin Immunother. 2025;21(1):2574129. https:\/\/doi.org\/10.1080\/21645515.2025.2574129.","journal-title":"Hum Vaccin Immunother"},{"issue":"9","key":"1434_CR75","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.3201\/eid1709.101762","volume":"17","author":"DAA Ala\u2019Aldeen","year":"2011","unstructured":"Ala\u2019Aldeen DAA, Oldfield NJ, Bidmos FA, et al. Carriage of meningococci by university students United Kingdom. Emerg Infect Dis. 2011;17(9):1762. https:\/\/doi.org\/10.3201\/eid1709.101762.","journal-title":"Emerg Infect Dis"},{"issue":"1","key":"1434_CR76","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.vaccine.2017.11.040","volume":"36","author":"L Breakwell","year":"2018","unstructured":"Breakwell L, Whaley M, Khan UI, et al. Meningococcal carriage among a university student population - United States, 2015. Vaccine. 2018;36(1):29\u201335. https:\/\/doi.org\/10.1016\/j.vaccine.2017.11.040.","journal-title":"Vaccine"},{"issue":"6","key":"1434_CR77","doi-asserted-by":"publisher","first-page":"950","DOI":"10.3201\/eid1206.051297","volume":"12","author":"J MacLennan","year":"2006","unstructured":"MacLennan J, Kafatos G, Neal K, et al. Social behavior and meningococcal carriage in British teenagers. Emerg Infect Dis. 2006;12(6):950\u20137. https:\/\/doi.org\/10.3201\/eid1206.051297.","journal-title":"Emerg Infect Dis"},{"issue":"9508","key":"1434_CR78","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/S0140-6736(06)67932-4","volume":"367","author":"MJ Thompson","year":"2006","unstructured":"Thompson MJ, Ninis N, Perera R, et al. Clinical recognition of meningococcal disease in children and adolescents. Lancet. 2006;367(9508):397\u2013403. https:\/\/doi.org\/10.1016\/S0140-6736(06)67932-4.","journal-title":"Lancet"},{"issue":"2","key":"1434_CR79","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1016\/j.jadohealth.2009.11.220","volume":"46","author":"SI Pelton","year":"2010","unstructured":"Pelton SI. Meningococcal disease awareness: clinical and epidemiological factors affecting prevention and management in adolescents. J Adolesc Health. 2010;46(2):S9\u201315. https:\/\/doi.org\/10.1016\/j.jadohealth.2009.11.220.","journal-title":"J Adolesc Health"},{"issue":"1","key":"1434_CR80","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2023.2186111","volume":"19","author":"M-K Taha","year":"2023","unstructured":"Taha M-K, Bekkat-Berkani R, Abitbol V. Changing patterns of invasive meningococcal disease and future immunization strategies. Hum Vaccin Immunother. 2023;19(1):2186111. https:\/\/doi.org\/10.1080\/21645515.2023.2186111.","journal-title":"Hum Vaccin Immunother"},{"key":"1434_CR81","unstructured":"U.S. Centers for Disease Control and Prevention. 2023 EMDS Surveillance Report. https:\/\/www.cdc.gov\/meningococcal\/media\/pdfs\/2025\/04\/NCIRD-EMDS-Report-2023_508.pdf."},{"issue":"1","key":"1434_CR82","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2024.2406613","volume":"20","author":"S Begum","year":"2024","unstructured":"Begum S, Herrera-Restrepo O, Rolland C, et al. Inequalities in the risk and prevention of invasive meningococcal disease in the United States\u2013a systematic literature review. Hum Vaccin Immunother. 2024;20(1):2406613. https:\/\/doi.org\/10.1080\/21645515.2024.2406613.","journal-title":"Hum Vaccin Immunother"},{"issue":"10","key":"1434_CR83","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1097\/00006454-200010000-00009","volume":"19","author":"M Baker","year":"2000","unstructured":"Baker M, McNicholas A, Garrett N, et al. Household crowding a major risk factor for epidemic meningococcal disease in Auckland children. Pediatr Infect Dis J. 2000;19(10):983\u201390.","journal-title":"Pediatr Infect Dis J"},{"key":"1434_CR84","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijid.2022.03.032","volume":"119","author":"H Dubey","year":"2022","unstructured":"Dubey H, Oster P, Fazeli MS, et al. Risk factors for contracting invasive meningococcal disease and related mortality: a systematic literature review and meta-analysis. Int J Infect Dis. 2022;119:1\u20139. https:\/\/doi.org\/10.1016\/j.ijid.2022.03.032.","journal-title":"Int J Infect Dis"},{"issue":"2","key":"1434_CR85","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines11020256","volume":"11","author":"C Masaquel","year":"2023","unstructured":"Masaquel C, Schley K, Wright K, et al. The impact of social determinants of health on meningococcal vaccination awareness, delivery, and coverage in adolescents and young adults in the United States: a systematic review. Vaccines (Basel). 2023;11(2):256. https:\/\/doi.org\/10.3390\/vaccines11020256.","journal-title":"Vaccines (Basel)"},{"issue":"2","key":"1434_CR86","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.jadohealth.2025.09.030","volume":"78","author":"CR Wells","year":"2026","unstructured":"Wells CR, Shoukat A, Shin T, Galvani AP, Moghadas SM. Racial and ethnic disparities in meningococcal vaccination coverage and disease burden among U.S. adolescents. J Adolesc Health. 2026;78(2):308\u201314. https:\/\/doi.org\/10.1016\/j.jadohealth.2025.09.030.","journal-title":"J Adolesc Health"},{"issue":"3","key":"1434_CR87","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s41999-024-00969-0","volume":"15","author":"C Weil-Olivier","year":"2024","unstructured":"Weil-Olivier C, Taha M-K, Leng S, et al. Invasive meningococcal disease in older adults: current perspectives and call for action. Eur Geriatr Med. 2024;15(3):729\u201341. https:\/\/doi.org\/10.1007\/s41999-024-00969-0.","journal-title":"Eur Geriatr Med"},{"issue":"3","key":"1434_CR88","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.jinf.2019.12.008","volume":"80","author":"K Beebeejaun","year":"2020","unstructured":"Beebeejaun K, Parikh SR, Campbell H, et al. Invasive meningococcal disease: timing and cause of death in England, 2008-2015. J Infect. 2020;80(3):286\u201390. https:\/\/doi.org\/10.1016\/j.jinf.2019.12.008.","journal-title":"J Infect"},{"issue":"2","key":"1434_CR89","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s40121-025-01281-5","volume":"15","author":"M-K Taha","year":"2026","unstructured":"Taha M-K, Weil-Olivier C, Leng S, Dinleyici EC, Yezli S. Meningococcal disease in older adults: challenges in diagnosis and management. Infect Dis Ther. 2026;15(2):443\u201359. https:\/\/doi.org\/10.1007\/s40121-025-01281-5.","journal-title":"Infect Dis Ther"},{"key":"1434_CR90","doi-asserted-by":"publisher","DOI":"10.1186\/s41479-019-0062-0","volume":"11","author":"C Feldman","year":"2019","unstructured":"Feldman C, Anderson R. Meningococcal pneumonia: a review. Pneumonia (London). 2019;11:3. https:\/\/doi.org\/10.1186\/s41479-019-0062-0.","journal-title":"Pneumonia (London)"},{"issue":"12","key":"1434_CR91","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1086\/379719","volume":"37","author":"P Vienne","year":"2003","unstructured":"Vienne P, Ducos-Galand M, Guiyoule A, et al. The role of particular strains of Neisseria meningitidis in meningococcal arthritis, pericarditis, and pneumonia. Clin Infect Dis. 2003;37(12):1639\u201342. https:\/\/doi.org\/10.1086\/379719.","journal-title":"Clin Infect Dis"},{"key":"1434_CR92","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2025.1511086","volume":"13","author":"E Ciftci","year":"2025","unstructured":"Ciftci E, Ocal D, Somer A, et al. Current methods in the diagnosis of invasive meningococcal disease. Front Pediatr. 2025;13:1511086. https:\/\/doi.org\/10.3389\/fped.2025.1511086.","journal-title":"Front Pediatr"},{"issue":"4","key":"1434_CR93","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1007\/s42770-022-00826-x","volume":"53","author":"MN Carnalla-Barajas","year":"2022","unstructured":"Carnalla-Barajas MN, Soto-Noguer\u00f3n A, Mart\u00ednez-Medina L, et al. Diagnosis of bacterial meningitis caused by Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae using a multiplex real-time PCR technique. Braz J Microbiol. 2022;53(4):1951\u20138. https:\/\/doi.org\/10.1007\/s42770-022-00826-x.","journal-title":"Braz J Microbiol"},{"issue":"6","key":"1434_CR94","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1007\/s40273-025-01477-0","volume":"43","author":"HA Shah","year":"2025","unstructured":"Shah HA, Jutlla G, Herrera-Restrepo O, et al. Market and non-market productivity losses associated with invasive meningococcal disease in the USA. Pharmacoeconomics. 2025;43(6):651\u201364. https:\/\/doi.org\/10.1007\/s40273-025-01477-0.","journal-title":"Pharmacoeconomics"},{"issue":"16","key":"1434_CR95","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1016\/j.vaccine.2017.03.007","volume":"35","author":"R Whittaker","year":"2017","unstructured":"Whittaker R, Dias JG, Ramliden M, et al. The epidemiology of invasive meningococcal disease in EU\/EEA countries, 2004-2014. Vaccine. 2017;35(16):2034\u201341. https:\/\/doi.org\/10.1016\/j.vaccine.2017.03.007.","journal-title":"Vaccine"},{"issue":"1","key":"1434_CR96","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-022-12795-9","volume":"22","author":"S Guedes","year":"2022","unstructured":"Guedes S, Bertrand-Gerentes I, Evans K, Coste F, Oster P. Invasive meningococcal disease in older adults in North America and Europe: is this the time for action? a review of the literature. BMC Public Health. 2022;22(1):380. https:\/\/doi.org\/10.1186\/s12889-022-12795-9.","journal-title":"BMC Public Health"},{"issue":"1","key":"1434_CR97","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1080\/14760584.2019.1557520","volume":"18","author":"R Acevedo","year":"2019","unstructured":"Acevedo R, Bai X, Borrow R, et al. The Global Meningococcal Initiative meeting on prevention of meningococcal disease worldwide: epidemiology, surveillance, hypervirulent strains, antibiotic resistance and high-risk populations. Expert Rev Vaccines. 2019;18(1):15\u201330. https:\/\/doi.org\/10.1080\/14760584.2019.1557520.","journal-title":"Expert Rev Vaccines"},{"issue":"7539","key":"1434_CR98","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1136\/bmj.38725.728472.BE","volume":"332","author":"J Tully","year":"2006","unstructured":"Tully J, Viner RM, Coen PG, et al. Risk and protective factors for meningococcal disease in adolescents: matched cohort study. BMJ. 2006;332(7539):445\u201350. https:\/\/doi.org\/10.1136\/bmj.38725.728472.BE.","journal-title":"BMJ"},{"issue":"1","key":"1434_CR99","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1186\/s12879-025-11954-8","volume":"25","author":"X Duval","year":"2025","unstructured":"Duval X, Collin C, Baloche A, Fanchon L, Nora T, Hoen B. Healthcare costs of invasive meningococcal disease: a nationwide population-based study using an innovative clustering method to identify sequelae. BMC Infect Dis. 2025;25(1):1537. https:\/\/doi.org\/10.1186\/s12879-025-11954-8.","journal-title":"BMC Infect Dis"},{"issue":"10","key":"1434_CR100","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1007\/s40273-018-0679-5","volume":"36","author":"B Wang","year":"2018","unstructured":"Wang B, Santoreneos R, Afzali H, Giles L, Marshall H. Costs of invasive meningococcal disease: a global systematic review. Pharmacoeconomics. 2018;36(10):1201\u201322. https:\/\/doi.org\/10.1007\/s40273-018-0679-5.","journal-title":"Pharmacoeconomics"},{"issue":"7","key":"1434_CR101","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s40273-013-0057-2","volume":"31","author":"A Anonychuk","year":"2013","unstructured":"Anonychuk A, Woo G, Vyse A, Demarteau N, Tricco AC. The cost and public health burden of invasive meningococcal disease outbreaks: a systematic review. Pharmacoeconomics. 2013;31(7):563\u201376. https:\/\/doi.org\/10.1007\/s40273-013-0057-2.","journal-title":"Pharmacoeconomics"},{"issue":"24","key":"1434_CR102","doi-asserted-by":"publisher","first-page":"663","DOI":"10.15585\/mmwr.mm7224a4","volume":"72","author":"AB Rubis","year":"2023","unstructured":"Rubis AB, Howie RL, Marasini D, Sharma S, Marjuki H, McNamara LA. Notes from the field: increase in meningococcal disease among persons with HIV - United States, 2022. MMWR Morb Mortal Wkly Rep. 2023;72(24):663\u20134. https:\/\/doi.org\/10.15585\/mmwr.mm7224a4.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"1434_CR103","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1186\/s12879-019-4146-5","volume":"19","author":"SN Ladhani","year":"2019","unstructured":"Ladhani SN, Campbell H, Lucidarme J, et al. Invasive meningococcal disease in patients with complement deficiencies: a case series (2008\u20132017). BMC Infect Dis. 2019;19:522. https:\/\/doi.org\/10.1186\/s12879-019-4146-5.","journal-title":"BMC Infect Dis"},{"issue":"5","key":"1434_CR104","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1093\/cid\/cix438","volume":"65","author":"TA Folaranmi","year":"2017","unstructured":"Folaranmi TA, Kretz CB, Kamiya H, et al. Increased risk for meningococcal disease among men who have sex with men in the United States, 2012-2015. Clin Infect Dis. 2017;65(5):756\u201363. https:\/\/doi.org\/10.1093\/cid\/cix438.","journal-title":"Clin Infect Dis"},{"issue":"8","key":"1434_CR105","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.3201\/eid2108.141837","volume":"21","author":"MM Kratz","year":"2015","unstructured":"Kratz MM, Weiss D, Ridpath A, et al. Community-based outbreak of Neisseria meningitidis serogroup C infection in men who have sex with men, New York City, New York, USA, 2010\u20132013. Emerg Infect Dis. 2015;21(8):1379\u201386. https:\/\/doi.org\/10.3201\/eid2108.141837.","journal-title":"Emerg Infect Dis"},{"issue":"38","key":"1434_CR106","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.15585\/mmwr.mm6738a4","volume":"67","author":"CH Bozio","year":"2018","unstructured":"Bozio CH, Blain A, MacNeil J, et al. Meningococcal disease surveillance in men who have sex with men - United States, 2015-2016. MMWR Morb Mortal Wkly Rep. 2018;67(38):1060\u20133. https:\/\/doi.org\/10.15585\/mmwr.mm6738a4.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"43","key":"1434_CR107","doi-asserted-by":"publisher","first-page":"973","DOI":"10.15585\/mmwr.mm7343a3","volume":"73","author":"M Robinson","year":"2024","unstructured":"Robinson M, Crain J, Kendall B, et al. Statewide outbreak of Neisseria meningitidis serogroup Y, sequence type 1466 - Virginia, 2022-2024. MMWR Morb Mortal Wkly Rep. 2024;73(43):973\u20137. https:\/\/doi.org\/10.15585\/mmwr.mm7343a3.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"1434_CR108","unstructured":"Chicago Department of Public Health. Meningococcal Outbreak Grows to 10 \u2013 Vaccination Recommended for People Experiencing Homelessness https:\/\/www.chicagohan.org\/it\/alert-detail?p_p_id=hanalertdetailsweb&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=download&p_p_cacheability=cacheLevelPage&_hanalertdetailsweb_attachmentId=45710657&_hanalertdetailsweb_priv_r_p_alertId=46691879."},{"key":"1434_CR109","unstructured":"Chicago Department of Public Health. Meningococcal Disease Update. https:\/\/www.chicago.gov\/city\/en\/depts\/cdph\/provdrs\/health_protection_and_response\/news\/2026\/jan\/cdph-weekly-media-brief-01-30-2025.html."},{"key":"1434_CR110","unstructured":"Chicago Department of Public Health. CDPH Declares Meningococcal Outbreak Over. https:\/\/www.chicago.gov\/city\/en\/depts\/cdph\/provdrs\/health_protection_and_response\/news\/2026\/mar\/cdph-weekly-media-brief-03-05-2026.html."},{"issue":"1","key":"1434_CR111","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-022-07129-4","volume":"22","author":"SS Voss","year":"2022","unstructured":"Voss SS, Nielsen J, Valentiner-Branth P. Risk of sequelae after invasive meningococcal disease. BMC Infect Dis. 2022;22(1):148. https:\/\/doi.org\/10.1186\/s12879-022-07129-4.","journal-title":"BMC Infect Dis"},{"issue":"12","key":"1434_CR112","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.1007\/s40121-024-01060-8","volume":"13","author":"O Herrera-Restrepo","year":"2024","unstructured":"Herrera-Restrepo O, Afroz N, Cabrera ES, et al. Life after invasive meningococcal disease: insights from survivors and their caregivers. Infect Dis Ther. 2024;13(12):2563\u201379. https:\/\/doi.org\/10.1007\/s40121-024-01060-8.","journal-title":"Infect Dis Ther"},{"issue":"3","key":"1434_CR113","doi-asserted-by":"publisher","first-page":"e502","DOI":"10.1542\/peds.2008-0581","volume":"123","author":"J Borg","year":"2009","unstructured":"Borg J, Christie D, Coen PG, Booy R, Viner RM. Outcomes of meningococcal disease in adolescence: prospective, matched-cohort study. Pediatrics. 2009;123(3):e502\u20139. https:\/\/doi.org\/10.1542\/peds.2008-0581.","journal-title":"Pediatrics"},{"issue":"1","key":"1434_CR114","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/INF.0b013e3181ef25f7","volume":"30","author":"A Chandran","year":"2011","unstructured":"Chandran A, Herbert H, Misurski D, Santosham M. Long-term sequelae of childhood bacterial meningitis: an underappreciated problem. Pediatr Infect Dis J. 2011;30(1):3\u20136. https:\/\/doi.org\/10.1097\/INF.0b013e3181ef25f7.","journal-title":"Pediatr Infect Dis J"},{"issue":"4","key":"1434_CR115","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1093\/jpids\/piv065","volume":"5","author":"L Strifler","year":"2016","unstructured":"Strifler L, Morris SK, Dang V, et al. The health burden of invasive meningococcal disease: a systematic review. J Pediatric Infect Dis Soc. 2016;5(4):417\u201330. https:\/\/doi.org\/10.1093\/jpids\/piv065.","journal-title":"J Pediatric Infect Dis Soc"},{"issue":"1","key":"1434_CR116","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-022-13342-2","volume":"22","author":"J Shen","year":"2022","unstructured":"Shen J, Begum N, Ruiz-Garcia Y, Martinon-Torres F, Bekkat-Berkani R, Meszaros K. Range of invasive meningococcal disease sequelae and health economic application - a systematic and clinical review. BMC Public Health. 2022;22(1):1078. https:\/\/doi.org\/10.1186\/s12889-022-13342-2.","journal-title":"BMC Public Health"},{"issue":"3","key":"1434_CR117","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1097\/INF.0000000000002251","volume":"38","author":"E Rampakakis","year":"2019","unstructured":"Rampakakis E, Vaillancourt J, Mursleen S, Sampalis JS. Healthcare resource utilization and cost of invasive meningococcal disease in Ontario, Canada. Pediatr Infect Dis J. 2019;38(3):253\u20137. https:\/\/doi.org\/10.1097\/INF.0000000000002251.","journal-title":"Pediatr Infect Dis J"},{"issue":"2","key":"1434_CR118","doi-asserted-by":"publisher","DOI":"10.1016\/j.bjid.2025.104514","volume":"29","author":"NTS Filha","year":"2025","unstructured":"Filha NTS, Cortes F, Kron M, et al. Treatment costs of long-term invasive meningococcal disease sequelae: a literature review and Delphi study in Brazil. Braz J Infect Dis. 2025;29(2):104514. https:\/\/doi.org\/10.1016\/j.bjid.2025.104514.","journal-title":"Braz J Infect Dis"},{"issue":"1","key":"1434_CR119","doi-asserted-by":"publisher","first-page":"96","DOI":"10.4161\/hv.7.1.13692","volume":"7","author":"KL Davis","year":"2011","unstructured":"Davis KL, Misurski D, Miller JM, Bell TJ, Bapat B. Cost of acute hospitalization and post-discharge follow-up care for meningococcal disease in the US. Hum Vaccin. 2011;7(1):96\u2013101. https:\/\/doi.org\/10.4161\/hv.7.1.13692.","journal-title":"Hum Vaccin"},{"issue":"1","key":"1434_CR120","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-025-25726-1","volume":"26","author":"T Shin","year":"2025","unstructured":"Shin T, Cristeau O, Upegui A, et al. Modelling the epidemiological impact and cost-effectiveness of possible changes to the meningococcal vaccination schedule for adolescents and young adults in the United States. BMC Public Health. 2025;26(1):452. https:\/\/doi.org\/10.1186\/s12889-025-25726-1.","journal-title":"BMC Public Health"},{"issue":"5","key":"1434_CR121","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1080\/14760584.2022.2052048","volume":"21","author":"M-K Taha","year":"2022","unstructured":"Taha M-K, Martinon-Torres F, K\u00f6llges R, et al. Equity in vaccination policies to overcome social deprivation as a risk factor for invasive meningococcal disease. Expert Rev Vaccines. 2022;21(5):659\u201374. https:\/\/doi.org\/10.1080\/14760584.2022.2052048.","journal-title":"Expert Rev Vaccines"},{"issue":"1","key":"1434_CR122","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-024-19740-y","volume":"24","author":"BR Morello","year":"2024","unstructured":"Morello BR, Milazzo A, Marshall HS, Giles LC. Public health management of invasive meningococcal disease outbreaks: worldwide 1973-2018, a systematic review. BMC Public Health. 2024;24(1):2254. https:\/\/doi.org\/10.1186\/s12889-024-19740-y.","journal-title":"BMC Public Health"},{"key":"1434_CR123","unstructured":"MEDQUAFDI (MenACYW). Prescribing information. Sanofi Pasteur Inc.; 2025."},{"issue":"1","key":"1434_CR124","doi-asserted-by":"publisher","first-page":"2160600","DOI":"10.1080\/21645515.2022.2160600","volume":"19","author":"CA Robertson","year":"2023","unstructured":"Robertson CA, Jacqmein J, Selmani A, Galarza K, Oster P. Immunogenicity and safety of a quadrivalent meningococcal conjugate vaccine (MenACYW-TT) administered as a booster to adults aged \u226559 years: a phase III randomized study. Hum Vacc Immunother. 2023;19(1):2160600. https:\/\/doi.org\/10.1080\/21645515.2022.2160600.","journal-title":"Hum Vacc Immunother"},{"issue":"5","key":"1434_CR125","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s40266-013-0065-0","volume":"30","author":"G Dbaibo","year":"2013","unstructured":"Dbaibo G, El-Ayoubi N, Ghanem S, et al. Immunogenicity and safety of a quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) administered to adults aged 56 years and older: results of an open-label, randomized, controlled trial. Drugs Aging. 2013;30(5):309\u201319. https:\/\/doi.org\/10.1007\/s40266-013-0065-0.","journal-title":"Drugs Aging"},{"key":"1434_CR126","unstructured":"Khaja H. CDC issues updated guidance on pentavalent meningococcal vaccine options. Infect Dis Advisor 2026. https:\/\/www.infectiousdiseaseadvisor.com\/news\/cdc-pentavalent-meningococcal-vaccine-guidance\/. Accessed April 8, 2026."},{"issue":"49","key":"1434_CR127","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.15585\/mmwr.mm7349a3","volume":"73","author":"S Schillie","year":"2024","unstructured":"Schillie S, Loehr J, Chen WH, et al. New dosing interval and schedule for the Bexsero MenB-4C vaccine: updated recommendations of the Advisory Committee on Immunization Practices \u2014 United States, October 2024. MMWR Morb Mortal Wkly Rep. 2024;73(49):1124\u20138. https:\/\/doi.org\/10.15585\/mmwr.mm7349a3.","journal-title":"MMWR Morb Mortal Wkly Rep."},{"key":"1434_CR128","doi-asserted-by":"publisher","first-page":"161","DOI":"10.2147\/IDR.S21545","volume":"4","author":"A Terranella","year":"2011","unstructured":"Terranella A, Cohn A, Clark T. Meningococcal conjugate vaccines: optimizing global impact. Infect Drug Resist. 2011;4:161\u20139. https:\/\/doi.org\/10.2147\/IDR.S21545.","journal-title":"Infect Drug Resist"},{"key":"1434_CR129","unstructured":"Advisory Committee on Immunization Practices (ACIP). Evidence to recommendations for serogroup B meningococcal vaccine booster dose recommendations in persons at increased risk of meningococcal disease during an outbreak. https:\/\/www.cdc.gov\/acip\/evidence-to-recommendations\/mening-risk-etr.html."},{"issue":"3","key":"1434_CR130","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1097\/INF.0000000000003033","volume":"40","author":"J Fergie","year":"2021","unstructured":"Fergie J, Howard A, Huang L, Srivastava A. Implementation experience with meningococcal serogroup B vaccines in the United States: impact of a nonroutine recommendation. Pediatr Infect Dis J. 2021;40(3):269\u201375. https:\/\/doi.org\/10.1097\/INF.0000000000003033.","journal-title":"Pediatr Infect Dis J"},{"issue":"3","key":"1434_CR131","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2018-0344","volume":"142","author":"A Kempe","year":"2018","unstructured":"Kempe A, Allison MA, MacNeil JR, et al. Adoption of serogroup B meningococcal vaccine recommendations. Pediatrics. 2018;142(3):e20180344. https:\/\/doi.org\/10.1542\/peds.2018-0344.","journal-title":"Pediatrics"},{"issue":"7","key":"1434_CR132","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.acap.2018.04.005","volume":"18","author":"A Kempe","year":"2018","unstructured":"Kempe A, Allison MA, MacNeil JR, et al. Knowledge and attitudes regarding category B ACIP recommendations among primary care providers for children. Acad Pediatr. 2018;18(7):763\u20138. https:\/\/doi.org\/10.1016\/j.acap.2018.04.005.","journal-title":"Acad Pediatr"},{"issue":"8","key":"1434_CR133","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/S1474-4422(23)00195-3","volume":"22","author":"GBD 2019 Meningitis Antimicrobial Resistance Collaborators","year":"2023","unstructured":"GBD 2019 Meningitis Antimicrobial Resistance Collaborators. Global, regional, and national burden of meningitis and its aetiologies, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Neurol. 2023;22(8):685\u2013711. https:\/\/doi.org\/10.1016\/S1474-4422(23)00195-3.","journal-title":"Lancet Neurol"},{"key":"1434_CR134","unstructured":"UK Health Security Agency. Childhood schedule changes 2025 and 2026: information for healthcare practitioners. https:\/\/www.gov.uk\/government\/publications\/childhood-schedule-changes-from-1-july-2025-information-for-healthcare-practitioners."},{"key":"1434_CR135","unstructured":"European Centre for Disease Prevention and Control. Meningococcal disease: recommended vaccinations. https:\/\/vaccine-schedule.ecdc.europa.eu\/Scheduler\/ByDisease?SelectedDiseaseId=48. Accessed March 7, 2026."},{"issue":"1","key":"1434_CR136","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jval.2020.09.004","volume":"24","author":"E Beck","year":"2021","unstructured":"Beck E, Klint J, Neine M, Garcia S, Meszaros K. Cost-effectiveness of 4CMenB infant vaccination in England: a comprehensive valuation considering the broad impact of serogroup B invasive meningococcal disease. Value Health. 2021;24(1):91\u2013104. https:\/\/doi.org\/10.1016\/j.jval.2020.09.004.","journal-title":"Value Health"},{"issue":"16","key":"1434_CR137","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1016\/j.vaccine.2021.02.049","volume":"39","author":"IB Nwogu","year":"2021","unstructured":"Nwogu IB, Jones M, Langley T. Economic evaluation of meningococcal serogroup B (MenB) vaccines: a systematic review. Vaccine. 2021;39(16):2201\u201313. https:\/\/doi.org\/10.1016\/j.vaccine.2021.02.049.","journal-title":"Vaccine"},{"issue":"12","key":"1434_CR138","doi-asserted-by":"publisher","first-page":"1649.e1","DOI":"10.1016\/j.cmi.2022.07.004","volume":"28","author":"JP Carr","year":"2022","unstructured":"Carr JP, MacLennan JM, Plested E, et al. Impact of meningococcal ACWY conjugate vaccines on pharyngeal carriage in adolescents: evidence for herd protection from the UK MenACWY programme. Clin Microbiol Infect. 2022;28(12):1649.e1-e8. https:\/\/doi.org\/10.1016\/j.cmi.2022.07.004.","journal-title":"Clin Microbiol Infect"},{"issue":"9960","key":"1434_CR139","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1016\/S0140-6736(14)60842-4","volume":"384","author":"RC Read","year":"2014","unstructured":"Read RC, Baxter D, Chadwick DR, et al. Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial. Lancet. 2014;384(9960):2123\u201331. https:\/\/doi.org\/10.1016\/S0140-6736(14)60842-4.","journal-title":"Lancet"},{"key":"1434_CR140","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268823000870","volume":"151","author":"L Hadley","year":"2023","unstructured":"Hadley L, Karachaliou Prasinou A, Christensen H, Ramsay M, Trotter C. Modelling the impact of COVID-19 and routine MenACWY vaccination on meningococcal carriage and disease in the UK. Epidemiol Infect. 2023;151:e98. https:\/\/doi.org\/10.1017\/S0950268823000870.","journal-title":"Epidemiol Infect"},{"issue":"5","key":"1434_CR141","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1586\/14760584.2016.1130628","volume":"15","author":"V Vetter","year":"2016","unstructured":"Vetter V, Baxter R, Denizer G, et al. Routinely vaccinating adolescents against meningococcus: targeting transmission & disease. Expert Rev Vaccines. 2016;15(5):641\u201358. https:\/\/doi.org\/10.1586\/14760584.2016.1130628.","journal-title":"Expert Rev Vaccines"},{"issue":"7 Suppl 2","key":"1434_CR142","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1016\/j.amjmed.2008.05.005","volume":"121","author":"DR Johnson","year":"2008","unstructured":"Johnson DR, Nichol KL, Lipczynski K. Barriers to adult immunization. Am J Med. 2008;121(7 Suppl 2):S28-35. https:\/\/doi.org\/10.1016\/j.amjmed.2008.05.005.","journal-title":"Am J Med"},{"key":"1434_CR143","unstructured":"Kolman S. Lawmakers turn to data systems to guide vaccine decision-making. https:\/\/www.ncsl.org\/state-legislatures-news\/details\/lawmakers-turn-to-data-systems-to-guide-vaccine-decision-making. Accessed April 28, 2026."},{"issue":"2","key":"1434_CR144","doi-asserted-by":"publisher","first-page":"30","DOI":"10.15585\/mmwr.mm7402a3","volume":"74","author":"AP Wodi","year":"2025","unstructured":"Wodi AP, Issa AN, Moser CA, Cineas S. Advisory Committee on Immunization Practices recommended immunization schedule for adults aged 19 years or older - United States, 2025. MMWR Morb Mortal Wkly Rep. 2025;74(2):30\u20133. https:\/\/doi.org\/10.15585\/mmwr.mm7402a3.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"21","key":"1434_CR145","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13216537","volume":"13","author":"P Garg","year":"2024","unstructured":"Garg P, Pareek S, Kulkarni P, Horne D, Salgia R, Singhal SS. Next-generation immunotherapy: advancing clinical applications in cancer treatment. J Clin Med. 2024;13(21):6537. https:\/\/doi.org\/10.3390\/jcm13216537.","journal-title":"J Clin Med"},{"issue":"1","key":"1434_CR146","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s44337-024-00029-3","volume":"1","author":"Y Sharma","year":"2024","unstructured":"Sharma Y, Arora M, Bala K. The potential of immunomodulators in shaping the future of healthcare. Discov Med (Singap). 2024;1(1):37. https:\/\/doi.org\/10.1007\/s44337-024-00029-3.","journal-title":"Discov Med (Singap)"},{"issue":"6","key":"1434_CR147","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.anai.2023.02.010","volume":"130","author":"L Cannon","year":"2023","unstructured":"Cannon L, Pan A, Kovalick L, Sarkissian A, Wu EY. Secondary immunodeficiencies and infectious considerations of biologic immunomodulatory therapies. Ann Allergy Asthma Immunol. 2023;130(6):718\u201326. https:\/\/doi.org\/10.1016\/j.anai.2023.02.010.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"1434_CR148","unstructured":"Centers for Disease Control and Prevention. Meningococcal Disease Cases Linked to Travel to the Kingdom of Saudi Arabia (KSA): Ensure Pilgrims Are Current on Meningococcal Vaccination. CDC Health Alert Network (HAN). CDCHAN-00508 https:\/\/www.cdc.gov\/han\/2024\/han00508.html."},{"issue":"3","key":"1434_CR149","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s40273-024-01439-y","volume":"43","author":"HA Shah","year":"2025","unstructured":"Shah HA, Jutlla G, Herrera-Restrepo O, et al. Public health impact of introducing a pentavalent vaccine against invasive meningococcal disease in the United States. Pharmacoeconomics. 2025;43(3):311\u201329. https:\/\/doi.org\/10.1007\/s40273-024-01439-y.","journal-title":"Pharmacoeconomics"},{"key":"1434_CR150","unstructured":"Scott J. CIDRAP Op-Ed: Quiet dismantling: How \u2018shared decision-making\u2019 weakens vaccine policy and harms kids. 2026. https:\/\/www.cidrap.umn.edu\/childhood-vaccines\/cidrap-op-ed-quiet-dismantling-how-shared-decision-making-weakens-vaccine-policy. Accessed April 8, 2026."},{"key":"1434_CR151","unstructured":"Bhattacharya, Jay, Oz M, Makary M. Decision Memo - Adopting Revised Childhood and Adolescent Immunization Schedule. https:\/\/www.hhs.gov\/sites\/default\/files\/decision-memo-adopting-revised-childhood-adolescent-immunization-schedule.pdf."},{"key":"1434_CR152","unstructured":"Common Health Coalition. Summary of the AAP v. Kennedy Ruling. https:\/\/commonhealthcoalition.org\/wp-content\/uploads\/2026\/03\/AAP-Ruling-Explainer-v4.pdf."},{"key":"1434_CR153","unstructured":"American Academy of Arts & Sciences. Experts Assess Recent Changes to Vaccine Policy. https:\/\/www.amacad.org\/news\/vaccine-policy-changes-impact. Accessed June 15, 2026."},{"key":"1434_CR154","doi-asserted-by":"publisher","first-page":"1745660","DOI":"10.3389\/fcimb.2025.1745660","volume":"15","author":"M Matsuba","year":"2026","unstructured":"Matsuba M, Mahazu S, Shimuta K, Ablordey A, Takahashi H, Saito R. Development of a rapid, simple multiplex PCR-dipstick assay for the detection of Neisseria meningitidis serogroups in clinical isolates. Front Cell Infect Microbiol. 2026;15:1745660. https:\/\/doi.org\/10.3389\/fcimb.2025.1745660.","journal-title":"Front Cell Infect Microbiol"},{"key":"1434_CR155","doi-asserted-by":"publisher","DOI":"10.26633\/RPSP.2017.158","volume":"41","author":"L Helena De Oliveira","year":"2017","unstructured":"Helena De Oliveira L, Jauregui B, Carvalho AF, Giglio N. Impact and effectiveness of meningococcal vaccines: a review. Rev Panam Salud Publica. 2017;41:e158. https:\/\/doi.org\/10.26633\/RPSP.2017.158.","journal-title":"Rev Panam Salud Publica"},{"key":"1434_CR156","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"key":"1434_CR157","unstructured":"Huelin R, Iheanacho I, Payne K, Sandman K. What\u2019s in a name? Systematic and non-systematic literature reviews and why the distinction matters. 2015. https:\/\/www.evidera.com\/wp-content\/uploads\/2015\/06\/Whats-in-a-Name-Systematic-and-Non-Systematic-Literature-Reviews-and-Why-the-Distinction-Matters.pdf."}],"updated-by":[{"DOI":"10.1007\/s40121-026-01461-x","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:00:00Z","timestamp":1792195200000}}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-026-01434-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-026-01434-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-026-01434-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T08:15:08Z","timestamp":1792311308000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-026-01434-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,6]]},"references-count":157,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["1434"],"URL":"https:\/\/doi.org\/10.1007\/s40121-026-01434-0","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,6]]},"assertion":[{"value":"18 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: In this article, the sentence \u2018This outbreak, which had a CFR of 19.4%, predominantly affected individuals aged 30\u201360 years (64%; not usually high risk for IMD), and was thought to have originated from an unvaccinated healthcare provider.\u2019, should have read \u2018This outbreak, which had a CFR of 19.4%, predominantly affected individuals aged 30\u201360 years (64%; not usually high risk for IMD).\u2019","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2026","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40121-026-01461-x","URL":"https:\/\/doi.org\/10.1007\/s40121-026-01461-x","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Mary Bausch-Jurken is an employee of Sanofi US and may hold stock\/stock options in the company. Sean Leng declares receipt of consulting or advisory fees and in-kind research support from Sanofi and engaged in speaking for GSK on the Shingrix vaccine. Jana Shaw declares receipt of consulting fees from Sanofi and consulting or advisory fees, speaking and lecture fees, and travel reimbursement from GSK and Pfizer. Stephen Pelton has received honorarium from Sanofi for participation in advisory committee meetings on meningococcal disease, participation in a data and safety monitoring board study of pneumococcal vaccine, and as adjudicator for a Sanofi respiratory syncytial virus vaccine trial.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This is a literature review and does not contain any new studies with human participants or animals performed by any of the authors. Therefore, ethics committee approval was not required.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}